Effect of prostaglandin E2 injection on the structural properties of the rat patellar tendon
© Ferry et al; licensee BioMed Central Ltd. 2012
Received: 28 February 2011
Accepted: 9 January 2012
Published: 9 January 2012
Increased tendon production of the inflammatory mediator prostaglandin E2 (PGE2) has been suggested to be a potential etiologic agent in the development of tendinopathy. Repeated injection of PGE2 into tendon has been proposed as a potential animal model for studying treatments for tendinopathy. In contrast, nonsteroidal anti-inflammatory drugs (NSAIDs) which inhibit PGE2 production and are commonly prescribed in treating tendinopathy have been shown to impair the healing of tendon after acute injury in animal models. The contradictory literature suggests the need to better define the functional effects of PGE2 on tendon. Our objective was to characterize the effects of PGE2 injection on the biomechanical and biochemical properties of tendon and the activity of the animals. Our hypothesis was that weekly PGE2 injection to the rat patellar tendon would lead to inferior biomechanical properties.
Forty rats were divided equally into four groups. Three groups were followed for 4 weeks with the following peritendinous injection procedures: No injection (control), 4 weekly injections of saline (saline), 4 weekly injections of 800 ng PGE2 (PGE2-4 wks). The fourth group received 4 weekly injections of 800 ng PGE2 initially and was followed for a total of 8 weeks. All animals were injected bilaterally. The main outcome measurements included: the structural and material properties of the patellar tendon under tensile loading to failure, tendon collagen content, and weekly animal activity scores.
The ultimate load of PGE2-4 wks tendons at 4 weeks was significantly greater than control or saline group tendons. The stiffness and elastic modulus of the PGE2 injected tendons at 8 weeks was significantly greater than the control or saline tendons. No differences in animal activity, collagen content, or mean fibril diameter were observed between groups.
Four weekly peritendinous injections of PGE2 to the rat patellar tendon were not found to be an effective model of clinical tendinopathy. In contrast, improved structural and material properties of the patellar tendon were found after PGE2 injection. While PGE2 has been thought to have a contributory role in the development of tendinopathy and anti-inflammatory medications remain a common treatment, our results suggest a positive role of PGE2 in tendon remodeling in some circumstances.
Tendinopathy is a frequent source of pain and disability seen in clinical practice. Common sites of tendinopathy include the rotator cuff, the common extensor origin at the elbow, the patellar tendon, and the Achilles tendon. Histologically, tendinopathy is characterized by degeneration and disorganization of collagen fibrils, increased mucoid ground substance, and the notable absence of inflammatory cells . In the clinical setting, tendinopathy ranges from activity related pain to frank rupture. The pathophysiology behind development of this condition as well as the optimum treatment remains controversial. An ideal animal model of tendinopathy would produce similar histologic findings, would decrease biomechanical strength of the tendon, could be readily applied to different anatomic areas, and would share a common pathophysiology to human tendinopathies.
Several theories exist about the pathophysiology behind the development of tendinopathy, but most involve some type of cellular response induced by repetitive motions [2, 3]. One theory involves the local release of inflammatory mediators by fibroblasts in response to mechanical loading. Cyclical loading of tendon fibroblasts in vitro has been shown to increase local concentrations of PGE2 and leukotriene B4 [2, 3]. Cyclical loading has also been shown to increase PGE2 and nitric oxide levels in a tendon explant system . PGE2 has been implicated as a potential etiologic agent in the development of tendinopathy and as a possible inducer of degradative enzyme activity .
In attempts to determine how local prostaglandin levels may affect tendon in vivo, a few studies have investigated local injection of prostaglandin E1 (PGE1) or PGE2 as an animal model of tendinopathy. Sullo et al. injected the rat Achilles tendon with PGE1 and found increased cross sectional area and degenerative changes similar to human tendinopathy after 5 weeks . Khan et al. injected PGE2 into rabbit patellar tendons and found loss of collagen fiber organization and decreased collagen fibril diameter compared to controls . However, neither of these studies evaluated the effect of prostaglandin injection on the tendon biomechanical properties which are more functionally relevant to the risk of the tendon degenerating to a state for which the chance of rupture is elevated.
In contrast to the proposed role of prostaglandins in tendon degeneration, there exists alternative evidence that suggests a positive role of prostaglandins in tendon healing. Several acute tendon injury models have demonstrated that administration of cyclooxgenase inhibitors which act to decrease the production of prostaglandins during the healing period impair the biomechanical properties of the healing tissue [8, 9]. Furthermore, it has been suggested nonsteroidal anti-inflammatory drugs (NSAIDs) may negatively influence tendon healing in tendinopathy and may contribute to the failed healing response . Recent work has also shown that blockade of PGE2 production by NSAID intake can abolish exercise-induced increases in collagen synthesis in the human patellar tendon . Past studies have found local administration of PGE2 in muscle in rabbits to stimulate fibrous tissue formation suggesting anabolic effects .
The contradictory literature concerning the positive or negative role of prostaglandins on tendon suggests the need for studies to better define the functional biomechanical effects of local application of PGE2 on tendon. Our objective was to characterize the effects of PGE2 injection on the biomechanical and biochemical properties of tendon and the activity of the animals. Our hypothesis was that weekly PGE2 injection to the rat patellar tendon would lead to inferior biomechanical properties.
Animal care and procedure
Protocols were approved by the University Institutional Animal Care and Use Committee. A total of 40 retired-breeder female Sprague-Dawley rats (350-500 g) were obtained from a commercial breeder. Four different study groups of ten animals each were used. A control group underwent no injections. The remaining groups underwent weekly peritendinous injections into both patellar tendons with a 27 gauge needle and a 100 microliter syringe. The saline group received injection of 50 microliters of 0.9% sodium chloride. The PGE2-4 wks and PGE2-8 wks groups had injections of 800 ng of PGE2 (P5640, Sigma-Aldrich, St. Louis, MO) in 50 microliters of 0.9% sodium chloride. Injections were performed at 0,7,14, and 21 days. Animals were anesthetized with isoflurane and the knees were shaved using electric clippers. The skin was prepped with an alcohol solution and the knee was flexed to 90 degrees to tension the tendon. The tendon was then injected parallel thru its length to a point midway between the patella and tibial insertions . The India ink of practice injections in cadavers was found to distribute superficially from the tendon, but stay beneath the peritenon. Thus, while the injection was intratendinous it may better be described as peritendinous. Animals were returned to their cages and allowed food, water, and activity ad libitum. All groups were sacrificed at 28 days, except the PGE2-8 wks group which was sacrificed at 56 days.
In order to determine if there was some disability related to the injections or PGE2, we monitored animal activity relative to pre-injection levels. This was completed for 6 animals in the saline group and 6 animals in the PGE2-8 wks group. We used a photoelectric sensors system to monitor animal activity . The rats were housed in individual cages with the water source on one end and food on the other end. The photoelectric sensor (Q14, Banner Engineering, Minneapolis, MN) was set-up to bisect the mid-portion of the cage. The sensors were linked to a control module (Logo!, Siemens, New York, NY) that recorded a count each time the beam was crossed. One count was recorded each time the animal stepped into and subsequently out of the beam with a one-second delay. Total counts were recorded at daily intervals for the duration of the study. The seven daily counts across a week's interval were averaged to compute an average daily count for each week. The pre-injection daily count measurement was taken as the average of the daily activity counts during the 5 days pre-injection. The average daily count was used in the statistical analysis.
All animals were sacrificed by CO2 overdose and both hind limbs harvested. Half of the right specimens (N = 5 per group) were transferred to 10% neutral buffered formalin, sequentially decalcified, dehydrated, embedded in plastic, sectioned, stained with hematoxylin and eosin, and qualitatively examined for fiber arrangement and cellularity. The remaining right limb specimens were fixed for fibril diameter analysis. The left hind limb were placed in saline-soaked gauze and stored at -20°C until the time of mechanical testing. On the day of biomechanical testing, the quadriceps, patella, patellar tendon, and tibia were isolated and dissected free of other soft tissues.
The length of the tendon as viewed from the anterior side was measured using a digital micrometer. The cross sectional area of the tendon at its midpoint was measured using an area micrometer after 0.12 MPa of compression was applied for 2 minutes. Measurements were taken in triplicate and averaged. Spray irrigation with saline was used to keep the tissue moist during all procedures. Following dissection and measurement, the tibia was secured in a custom grip on a servohydraulic testing machine (8500; Instron, Norwood MA). The quadriceps muscle and tendon were secured in a custom designed cryogrip and the visible freeze line edge of the tissue was allowed to migrate to the superior edge of the patella. The tendon was preloaded to 0.5 N and then the complex was loaded to failure at a constant deformation rate of 0.08 mm/sec corresponding to a 1% strain rate per second. The load-deformation data was acquired via an analog to digital converter linked to a personal computer and the failure site was recorded. The structural properties of maximum load, linear stiffness between 25-75% load limits, energy absorbed, and deformation at ultimate load were determined as well as the corresponding material properties.
Following the biomechanical testing, the patellar tendon was harvested and stored at -20°C. At the time of evaluation, the tissue was thawed and then dehydrated. Dry weight was recorded and the tissue was then subjected to papain digestion (0.5 mg/ml, Sigma-Aldrich, St. Louis, MO) in a 0.1 M phosphate buffer (pH 7) with 10 mM Cystine HCL & 2 mM EDTA at 60°C for 6 hours. The digest was used for the determination of collagen content. Collagen content of the digest was measured by hydroxyproline concentration by the method of Bergman & Loxley with a plate reader . Standard curves were created using known concentrations of hydroxyproline (Sigma-Aldrich, St. Louis, MO).
Fibril Diameter Analysis
Tendons for this analysis (n = 5 per group for the control and PGE2-8 wks groups) were fixed in 2% paraformaldehyde/2.5% glutaraldehyde in 0.15 M sodium phosphate buffer, pH 7.4, for 24 hours followed by post-fixation in 1% osmium tetroxide in 0.15 M sodium phosphate buffer, pH 7.4, for 1 hour. Samples were dehydrated in a graded series of ethanols, followed by propylene oxide, and infiltrated and embedded in Polybed 812 resin (Polysciences, Inc., Warrington, PA). Tendon cross sections of 70 nm thickness were stained with 6% methanolic uranyl acetate and Reynolds' lead citrate. Sections were observed using a LEO EM-910 transmission electron microscope operating at 80 kV (Carl Zeiss SMT, Peabody, MA) and images were taken using a Gatan Orius SC1000 CCD camera with Digital Micrograph 3.11.0 (Gatan, Inc., Pleasanton, CA). Two regions of interest of (approximate size of 1.26 μm × 1.05 μm) from each of three images (approximate size of 5.41 μm × 3.84 μm) of each animal were used to compute the average fibril diameter. Fibril diameters were measured for all fibrils in the region of interest using a custom script written in a commercially available image analysis program (Vision 6.0, National Instruments Inc., Austin, TX).
Biomechanical parameters, collagen content, and collagen fibril diameters were evaluated with a one way ANOVA, followed by Holm-Sidak multiple comparison testing. Activity counts from preinjection to 8 weeks were analyzed using a two-way repeated measures ANOVA for the factors of time (repeated factor) and group.
Forty animals were included in the study. One animal was excluded from biomechanical testing in the PGE2-8 wks groups due to tissue damage during dissection and five specimens were excluded because the tensile failure occurred at the quadriceps insertion of the patella during biomechanical testing. The remaining specimens failed at the patellar tendon insertions at either the tibial tubercle (T) or patella (P). The failure site distribution for each group was as follows: Control (6P, 1T), Saline (7P, 2T), PGE2-4wks (7P, 2T), PGE2-8 wks (6P, 3T).
Material properties of the rat patellar tendon for the 4 groups (Mean ± SD)
Ultimate Stress (MPa)
Strain to Ultimate Load (mm/mm)
Elastic Modulus (MPa)
Energy Density to Ultimate Load (mJ/mm3)
26.2 ± 6.8
0.34 ± 0.08
84.5 ± 23.2
4.66 ± 2.38
21.6 ± 4.7
0.28 ± 0.06
83.2 ± 17.1
3.14 + 0.98
27.1 ± 5.3
0.31 ± 0.09
90.0 ± 18.2
4.47 + 1.67
28.2 ± 5.9
0.24 ± 0.05
124.0 ± 35.0*,#,+
3.96 ± 1.22
P = 0.091
P = 0.053
P = 0.004
P = 0.226
Structural properties of the rat patellar tendon for the 4 groups (Mean ± SD)
Energy to Ultimate Load (J)
Displacement at Ultimate Load (mm)
Cross-sectional area (mm2)
0.116 ± 0.053
2.64 ± 0.65
7.72 ± 0.57
3.30 ± 0.43
0.096 ± 0.028
2.18 ± 0.44
7.70 ± 0.25
3.98 ± 0.50*
0.132 ± 0.032
2.42 ± 0.65
7.81 ± 0.30
4.02 ± 0.75*
0.105 ± 0.029
1.87 ± 0.31*
7.66 ± 0.26
3.49 ± 0.28
P = 0.187
P = 0.036
P = 0.83
P = 0.021
The results from our study did not support the hypothesis that the biomechanical properties would be inferior after PGE2 injection, rather, PGE2 appeared to produce the opposite effect. In our study the local application of PGE2 improved the structural strength and structural/material stiffness properties of the tendon. The increase in stiffness was sustained 4 weeks after the injections were stopped at 4 weeks suggesting these improvements were not transient. The increase in cross-sectional area of the PGE2-4 wks tendons suggests that this improvement in structural properties initially resulted from tendon hypertrophy. This hypertrophy corresponds with recent work that has shown that inhibition of PGE2 production in vivo can block exercise-induced increases in collagen synthesis of the patellar tendon in humans . In addition, past work has shown local PGE2 administration to increase fibrous tissue formation in muscle in an in vivo rabbit model . The improvement in stiffness in the PGE2-8 wks tendons of our study may have been due material changes as the elastic modulus was increased. However, material changes were not detected in the collagen content or mean fibril diameter evaluations.
There are several possible explanations for the difference in tissue response observed in this study compared to the hypothesized degenerative tissue response based on previous reports [6, 7]. Our model may not have shown the degenerative effects if the dosage of PGE2 was inadequate, if the tendon was not exposed to PGE2 for a long enough time, or if the testing was completed at too early or late of a time point. The PGE2 injection model is likely an oversimplification of the complexity of clinical tendinopathy, and it is possible that administration of PGE2 in concert with exercise loading or additional inflammatory mediators that are upregulated with mechanical loading may lead to a tendon with degenerative properties. The dosage of PGE2 used in our study was similar to that used in a previous rabbit patellar tendon study observing a degenerative tissue response to PGE2 injection [6, 7]. It is possible that with the larger volume of the rabbit patellar tendon compared to the rat, the injected PGE2 solution may have had a greater propensity to remain intratendinously causing a greater effect on the internal fibroblasts and collagen fibrils. In our study some of the injection solution was observed to leak from the tendon, but stay beneath the peritenon. Thus, the internal fibroblast may have been exposed to lower concentrations of PGE2 than desired. This may have contributed to the lack of change in fibril diameter and matrix organization observed in this study as compared to previous work . If the collagen fibril changes to PGE2 injection reported in the previous rabbit patellar tendon model were a transient response, the slower rate of metabolism in the rabbit compared to the rat may have resulted in these changes dissipating prior to our examination in our rat model. The timing of our evaluation in our study was more extended than previous animal studies [6, 7]. This might suggest that previously reported histological changes may not have been degenerative changes but simply transient effects in the tissue prior to obtaining its superior structural properties.
An alternative explanation for our results is that the PGE2 production with tendon loading actually plays a positive role in stimulating tendon remodeling and that PGE2 alone is not the primary component of the pathologic development of tendinopathy. In support of PGE2's positive role in stimulating tendon remodeling, recent studies have shown that inhibitors of prostaglandin production, cyclooxgenase (COX) inhibitors, can impair the tensile strength of healing tendon tissue after transection injury [8, 9]. In interpreting these COX inhibitor studies it is important to consider that these studies do not simply involve reduction of PGE2, but can also influence other elements of arachidonic acid metabolism such as the production of leukotreines and PGD 2 [2, 3, 14]. Furthermore, the timing of the administration of COX inhibitors during tendon healing appears to be important as early administration appears to impair healing while delayed administration may improve the material properties of the tissue . It is also important to note that a number of in vitro studies of human tendon fibroblasts from healthy tissue have demonstrated negative effects of exogenous PGE2 exposure on proliferation, collagen synthesis, and tendon stem cell differentiation [5, 16]. In contrast, the findings of in vitro studies investigating the effect of COX inhibitors on tendon fibroblasts would suggest the opposite effect of PGE2 on proliferation as such inhibitors have been found to decrease cell proliferation [17, 18]. There will always be some uncertainty regarding whether the mechanical and biochemical environment of the in vitro setting are representative of the in vivo setting of tendon healing. Recent work has shown that cultured tendon cells of intact tendon do not demonstrate the same cellular activity as healing tendon cells . Furthermore, in vivo microdialysis studies examining the effect of COX inhibition on exercise-induced collagen synthesis would suggest that PGE2 increases collagen synthesis  as contrasted with in vitro work which suggests PGE2 decreases collagen synthesis . Finally, past studies have shown that the injection of fatty acid preparations that are similar to the arachidonic acid precursors of prostaglandins can increase the strength of ligament and tendon [20, 21]. Thus, it is apparent from these studies there still exists a great amount of uncertainty regarding the effects of PGE2 on tendon in vivo.
While there is little literature regarding the direct effect of prostaglandins on the biomechanical properties of tendon and ligament, there is a substantial body of evidence regarding the effects of prostaglandins on bone. Multiple in vivo studies have demonstrated an anabolic effect on bone with subcutaneous or systemic administration of prostaglandins. These studies have demonstrated increased bone formation in multiple sites with prostaglandin treatment as well as prevention of bone loss associated with disuse, immobilization, and ovariectomy [22–24]. Similar anabolic results have been found with local delivery of prostaglandins to bone [25–27]. On a historical note, it is important to recognize that the early in vitro studies of prostaglandins on bone focused on its resorption effects , while later it was realized that this resorption activity was often followed by increased bone formation that ultimately produced an increase in bone mass. It is unclear if the extensive past focus on the negative effects of PGE2 on tendon has limited the consideration of positive effects in tendon healing. While the elevated level of PGE2 seen with cyclical loading and exercise may contribute to the development of tendinopathy, our results suggests that they may play more of an adaptive role in improving tendon strength, similar to their role in bone remodeling.
Another factor which may explain how PGE2 may have both positive and negative effects may be in the relative expression of the cellular receptors which mediate the response to PGE2. It is known that the cellular response to PGE2 is mediated by four G-protein coupled EP receptors. In bone, it has been shown that the EP2 and EP4 receptors regulate the anabolic response to PGE2 and agonists to these receptors have been shown to accelerate fracture healing . It is unclear if the same EP receptors are anabolic for tendon as for bone and how receptor expression may change across stages of tendon healing. Receptor-selective EP agonists may allow for the positive effects of prostaglandins on tendon healing to be more effectively harnessed.
Our study was not without limitations. Early time points of evaluation were not included in the study and these may have helped capture early but transient responses of the tendon injections. Only one dosage was used, but this was the same dosage that was used in a past study that reported significant histological changes in tendon in a rat model . The method of PGE2 delivery, injection, may have also contributed to the tendon response. Finally, our sample size may not have provided us adequate power to detect differences in all of the evaluation measures.
Despite these limitations, our study provided the novel finding that weekly PGE2 injections for four weeks can cause an improvement in the biomechanical properties of tendon and these improvements can persist for 4 weeks after ceasing injections. Future studies will have to better determine the biophysical and biochemical mechanisms by which the PGE2 injections caused the improvement in biomechanical properties. Weekly injection of PGE2 alone in the rat patellar tendon model does not appear to mimic clinical tendinopathy, and at this stage it appears more study is needed before attempting to use a prostaglandin injection model to study treatments for human tendinopathies.
Four weekly peritendinous injections of PGE2 to the rat patellar tendon were not found to be an effective model of clinical tendinopathy. In contrast, improved structural properties of the patellar tendon were found after PGE2 injection. While PGE2 has been thought to have a contributory role in the development of tendinopathy and anti-inflammatory medications remain a common treatment, our results suggest a positive role of PGE2 in tendon remodeling in some circumstances.
Funding was provided by the UNC Orthopaedic Research Fund and the Aileen Stock Research Fund.
- Khan KM, Cook JL, Bonar F, Harcourt P, Astrom M: Histopathology of common tendinopathies. Update and implications for clinical management. Sports Med. 1999, 27: 393-408. 10.2165/00007256-199927060-00004.View ArticlePubMed
- Almekinders LC, Banes AJ, Ballenger CA: Effects of repetitive motion on human fibroblasts. Med Sci Sports Exerc. 1993, 25: 603-607.PubMed
- Li Z, Yang G, Khan M, Stone D, Woo SL, Wang JH: Inflammatory response of human tendon fibroblasts to cyclic mechanical stretching. Am J Sports Med. 2004, 32: 435-440. 10.1177/0095399703258680.View ArticlePubMed
- Flick J, Devkota A, Tsuzaki M, Almekinders L, Weinhold P: Cyclic loading alters biomechanical properties and secretion of PGE2 and NO from tendon explants. Clin Biomech (Bristol, Avon). 2006, 21: 99-106. 10.1016/j.clinbiomech.2005.08.008.View Article
- Cilli F, Khan M, Fu F, Wang JH: Prostaglandin E2 affects proliferation and collagen synthesis by human patellar tendon fibroblasts. Clin J Sport Med. 2004, 14: 232-236. 10.1097/00042752-200407000-00006.View ArticlePubMed
- Sullo A, Maffulli N, Capasso G, Testa V: The effects of prolonged peritendinous administration of PGE1 to the rat Achilles tendon: a possible animal model of chronic Achilles tendinopathy. J Orthop Sci. 2001, 6: 349-357. 10.1007/s007760100031.View ArticlePubMed
- Khan MH, Li Z, Wang JH: Repeated exposure of tendon to prostaglandin-E2 leads to localized tendon degeneration. Clin J Sport Med. 2005, 15: 27-33. 10.1097/00042752-200501000-00006.View ArticlePubMed
- Cohen DB, Kawamura S, Ehteshami JR, Rodeo SA: Indomethacin and celecoxib impair rotator cuff tendon-to-bone healing. Am J Sports Med. 2006, 34: 362-369.View ArticlePubMed
- Ferry ST, Dahners LE, Afshari HM, Weinhold PS: The effects of common anti-inflammatory drugs on the healing rat patellar tendon. Am J Sports Med. 2007, 35: 1326-1333. 10.1177/0363546507301584.View ArticlePubMed
- Chan KM, Fu SC: Anti-inflammatory management for tendon injuries - friends or foes?. Sports Med Arthrosc Rehabil Ther Technol. 2009, 1: 23-10.1186/1758-2555-1-23.PubMed CentralView ArticlePubMed
- Christensen B, Dandanell S, Kjaer M, Langberg H: Effect of anti-inflammatory medication on the running-induced rise in patella tendon collagen synthesis in humans. J Appl Physiol. 2011, 110: 137-141. 10.1152/japplphysiol.00942.2010.View ArticlePubMed
- Keller J, Schumacher B, Lind M: Effect of local prostaglandin E2 on periosteum and muscle in rabbits. Acta Orthop Scand. 1992, 63: 623-627.View ArticlePubMed
- Bergman I, Loxley R: Two improved and simplified methods for the spectrophotometric determination of hydroxyproline. Anal Chem. 1963, 35: 1961-1965. 10.1021/ac60205a053.View Article
- Gilroy DW, Colville-Nash PR, Willis D, Chivers J, Paul-Clark MJ, Willoughby DA: Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med. 1999, 5: 698-701. 10.1038/9550.View ArticlePubMed
- Virchenko O, Skoglund B, Aspenberg P: Parecoxib impairs early tendon repair but improves later remodeling. Am J Sports Med. 2004, 32: 1743-1747. 10.1177/0363546504263403.View ArticlePubMed
- Zhang J, Wang JH: Production of PGE(2) increases in tendons subjected to repetitive mechanical loading and induces differentiation of tendon stem cells into non-tenocytes. J Orthop Res. 2010, 28: 198-203.View ArticlePubMed
- Almekinders LC, Baynes AJ, Bracey LW: An in vitro investigation into the effects of repetitive motion and nonsteroidal antiinflammatory medication on human tendon fibroblasts. Am J Sports Med. 1995, 23: 119-123. 10.1177/036354659502300120.View ArticlePubMed
- Tsai WC, Hsu CC, Chou SW, Chung CY, Chen J, Pang JH: Effects of celecoxib on migration, proliferation and collagen expression of tendon cells. Connect Tissue Res. 2007, 48: 46-51. 10.1080/03008200601071295.View ArticlePubMed
- Fu SC, Cheuk YC, Chan KM, Hung LK, Wong MW: Is cultured tendon fibroblast a good model to study tendon healing?. J Orthop Res. 2008, 26: 374-383. 10.1002/jor.20483.View ArticlePubMed
- Aneja A, Karas SG, Weinhold PS, Afshari HM, Dahners LE: Suture plication, thermal shrinkage, and sclerosing agents: effects on rat patellar tendon length and biomechanical strength. Am J Sports Med. 2005, 33: 1729-1734. 10.1177/0363546505275492.View ArticlePubMed
- Liu YK, Tipton CM, Matthes RD, Bedford TG, Maynard JA, Walmer HC: An in situ study of the influence of a sclerosing solution in rabbit medial collateral ligaments and its junction strength. Connect Tissue Res. 1983, 11: 95-102. 10.3109/03008208309004846.View ArticlePubMed
- Ito H, Ke HZ, Jee WS, Sakou T: Anabolic responses of an adult cancellous bone site to prostaglandin E2 in the rat. Bone Miner. 1993, 21: 219-236. 10.1016/S0169-6009(08)80232-2.View ArticlePubMed
- Jee WS, Mori S, Li XJ, Chan S: Prostaglandin E2 enhances cortical bone mass and activates intracortical bone remodeling in intact and ovariectomized female rats. Bone. 1990, 11: 253-266. 10.1016/8756-3282(90)90078-D.View ArticlePubMed
- Jee WS, Akamine T, Ke HZ, Li XJ, Tang LY, Zeng QQ: Prostaglandin E2 prevents disuse-induced cortical bone loss. Bone. 1992, 13: 153-159. 10.1016/8756-3282(92)90005-H.View ArticlePubMed
- Marks SC, Miller S: Local infusion of prostaglandin E1 stimulates mandibular bone formation in vivo. J Oral Pathol. 1988, 17: 500-505. 10.1111/j.1600-0714.1988.tb01324.x.View ArticlePubMed
- Miller SC, Marks SC: Alveolar bone augmentation following the local administration of prostaglandin E1 by controlled-release pellets. Bone. 1993, 14: 587-593. 10.1016/8756-3282(93)90198-J.View ArticlePubMed
- Yang RS, Liu TK, Lin-Shiau SY: Increased bone growth by local prostaglandin E2 in rats. Calcif Tissue Int. 1993, 52: 57-61. 10.1007/BF00675627.View ArticlePubMed
- Norrdin RW, Jee WS, High WB: The role of prostaglandins in bone in vivo. Prostaglandins Leukot Essent Fatty Acids. 1990, 41: 139-149. 10.1016/0952-3278(90)90081-U.View ArticlePubMed
- Li M, Thompson DD, Paralkar VM: Prostaglandin E(2) receptors in bone formation. Int Orthop. 2007, 31: 767-772. 10.1007/s00264-007-0406-x.PubMed CentralView ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.